17.05.2014 Views

PEBC Report - Programa de Epigenética y Biología del Cáncer

PEBC Report - Programa de Epigenética y Biología del Cáncer

PEBC Report - Programa de Epigenética y Biología del Cáncer

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Dr Dave Monk<br />

Genomic Imprinting and Cancer Group<br />

David Monk (London, United Kingdom, 1975) graduated<br />

from Anglia Ruskin University, Cambridge with a B.Sc (Hons)<br />

in Biomedical science before un<strong>de</strong>rtaking an M.Sc in<br />

Human Reproductive Biology at Imperial College London.<br />

In 2001 he wrote his PhD thesis on the genetic aetiology of<br />

Silver-Russell syndrome, a project mentored by Professors<br />

Michael Preece and Gudrun Moore at Queen Charlotte’s<br />

and Chelsea Hospital (QCCH), Imperial College London.<br />

From 2001-2004 he was a Postdoctoral Researcher fun<strong>de</strong>d<br />

by the MRC to screen for novel imprinted genes using<br />

DNA methylation based technologies. This position was a<br />

multi-site collaborative project, which saw him spend time in<br />

the laboratories of Professor Moore, now at the Institute of<br />

Reproductive and Developmental Biology (IRDB) Imperial<br />

College London, Dr Gavin Kelsey at The Babraham Institute<br />

Cambridge, and with Professor Jo Peters at MRC Harwell.<br />

From 2005-2007, Dr Monk was a March of Dimes fun<strong>de</strong>d<br />

Postdoctoral Research Fellow at the IRDB, un<strong>de</strong>rtaking<br />

research into the epigenetic regulation of placental imprinting<br />

in the human, and the involvement of imprinted gene<br />

expression in human fetal growth. During this time he was<br />

awar<strong>de</strong>d an EMBO short-term fellowship to spend time in<br />

the laboratory of Dr Robert Feil in CNRS, Montpellier France.<br />

In 2007, he was appointed as Lecturer in Molecular<br />

Epigenetics and Paediatric Oncology at the Institute of Child<br />

Health, University College London. Since the summer of<br />

2008, Dr Monk is the Principal Investigator of the Genomic<br />

Imprinting and Cancer group within the Cancer Epigenetics<br />

and Biology Program of the Catalan Institute of Oncology<br />

(ICO) in Barcelona. His current research interests inclu<strong>de</strong>:<br />

Aberrant epigenetic modifications and imprinting in MLL<br />

translocation leukaemias; Altered DNA methylation and<br />

imprinting profiles in cancers; and <strong>de</strong>fining epigenetic signatures<br />

for loss-of-imprinting that occur in cancer and imprinting<br />

disor<strong>de</strong>rs.<br />

PhD Stu<strong>de</strong>nts: Amy Guilaumet Adkins,<br />

Alejandro Martin Trujillo<br />

Visiting Stu<strong>de</strong>nt: Alberto Garcia Lopez<br />

Epigenetics is the term used in biology to refer to chromatin<br />

structure and DNA modifications that are stable over rounds<br />

of cell division but do not involve changes in the DNA<br />

sequence. Epigenetics play a pivotal role in cellular differentiation,<br />

allowing cells to stably maintain different characteristics<br />

<strong>de</strong>spite containing the same genomic DNA. Epigenetic<br />

processes are also involved in gene silencing, X chromosome<br />

inactivation, reprogramming and are thought to be<br />

one of the major limitations to cloning. One of the main<br />

interests of this group is Genomic Imprinting. Imprinted<br />

genes are expressed from only one parental allele, the other<br />

is silenced by epigenetic modifications, classically involving<br />

43

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!